| NEKTAR THERAPEUTICS |
| USA |
| Gesundheit |
| US6402683063 / A419UB |
| ITH0 (Frankfurt) / NKTR (NASDAQ) |
| FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR |
| - |
| https://www.nektar.com/ |
|
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in drug discovery and development with a primary focus on immunotherapy. It operates within the biotechnology and he..
>Volltext.. |
| 1750.52 Mio. EUR |
| 1662.74 Mio. EUR |
| 53.12 Mio. EUR |
| -114.72 Mio. EUR |
| -102.45 Mio. EUR |
| -6.73 EUR |
| 141.78 Mio. EUR |
| 13.84 Mio. EUR |
| -161 Mio. EUR |
| 4.07 |
| -36.23% |
| 31.93% |
| - |
| - |
| - |
| NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC |
| 21.02.26 |